| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(29 days from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(1 year, 28 days from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(1 year, 28 days from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(1 year, 28 days from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(1 year, 3 months from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(7 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(7 years from now) | |
Mirvaso is owned by Galderma Labs Lp.
Mirvaso contains Brimonidine Tartrate.
Mirvaso has a total of 12 drug patents out of which 0 drug patents have expired.
Mirvaso was authorised for market use on 23 August, 2013.
Mirvaso is available in gel;topical dosage forms.
Mirvaso can be used as topical treatment of facial erythema of rosacea.
The generics of Mirvaso are possible to be released after 13 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
